Archive · 11 Aug 2025
Shilpa Medicare Receives Approval for NAFLD Drug
Imagine your liver is like a busy kitchen, and sometimes it gets too much fat.
This can cause a disease called NAFLD.
Shilpa Medicare has made a new medicine, like a special cleaner, to help.
India has approved it.
This medicine is the first of its kind, and Shilpa Medicare will be the first to sell it anywhere.
It helps the liver work better and fights the fat buildup.
Millions of people around the world have this problem, so this medicine could help many folks stay healthy.
Shilpa Medicare received approval for Nor Ursodeoxycholic Acid Tablets 500 mg.
The drug is for treating Non-Alcoholic Fatty Liver Disease (NAFLD).
It's the first-in-class treatment for NAFLD in India.
Shilpa Medicare will be the first company to launch this drug worldwide.
NAFLD affects a large portion of the global population.
- Who
- Shilpa Medicare
- What
- Approval of Nor Ursodeoxycholic Acid Tablets 500 mg.
- When
- August 11 (implied)
- Where
- India
- Why
- For the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD).
- Drug Name
- Nor Ursodeoxycholic Acid Tablets 500 mg
- Company
- Shilpa Medicare
- Disease
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Treatment Type
- First-in-class
- Global Prevalence
- 25% of the world's population
- India Prevalence
- 188 million individuals